EUPRAXIA PHARMACEUTICALS INC. EPRX
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.03
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — |
| R&D | $21.3M | $16.1M | $20.4M | $13.6M | — |
| SG&A | $17.1M | $10.9M | $7.5M | $4.0M | — |
| Total operating expenses | $38.4M | $27.0M | $27.8M | $17.6M | — |
| Interest expense | $0 | $603.6K | $1.2M | $982.9K | — |
| Pre-tax income | -$38.6M | -$25.7M | -$28.9M | -$19.0M | — |
| Income tax | $19.1K | $1.8K | $36.4K | $0 | — |
| Net income | -$38.6M | -$25.5M | -$28.2M | -$18.5M | — |
| EPS, basic | -1.03 | -0.76 | -1.17 | -0.96 | — |
| EPS, diluted | -1.03 | -0.76 | -1.17 | -0.96 | — |
| Shares, diluted (wtd. avg.) | 40.0M | 33.9M | 24.1M | 19.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $80.6M | $33.1M | $19.3M | $18.3M | $12.5M |
| Receivables | $716.1K | $258.1K | $153.7K | — | — |
| Total current assets | $85.1M | $34.4M | $19.8M | $18.6M | — |
| Property, plant and equipment | $834.4K | $357.9K | $409.6K | $443.5K | — |
| Total assets | $86.2M | $34.9M | $20.3M | $19.1M | — |
| Accounts payable | $942.2K | $376.5K | $1.3M | $1.8M | — |
| Total current liabilities | $5.6M | $3.1M | $19.4M | $3.1M | — |
| Total liabilities | $5.7M | $3.1M | $19.4M | $11.9M | — |
| Retained earnings | -$169.6M | -$131.0M | -$105.5M | -$77.3M | — |
| Total equity | $82.0M | $33.4M | $892.3K | $7.2M | $15.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$28.6M | -$30.0M | -$20.7M | -$14.4M | — |
| Depreciation and amortisation | $237.7K | $171.7K | $155.5K | $147.9K | — |
| Stock-based compensation | $8.8M | $3.2M | $1.4M | $1.4M | — |
| Investing cash flow | -$588.9K | -$75.2K | -$73.4K | $9.8M | — |
| Financing cash flow | $76.1M | $45.8M | $21.1M | $10.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-104765.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — |
| Net income | — | -$18.5M | -$28.2M | -$25.5M | -$38.6M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |